Most peptides in this corner of medicine have never been near an FDA approval. Sermorelin is the odd one out, and that history is the most interesting thing about it, so let's start there.
The part that makes sermorelin unusual
Sermorelin was once FDA-approved, sold under the brand name Geref, and used mainly to help evaluate growth hormone deficiency in children. Then the manufacturer voluntarily pulled it from the market years ago, for commercial reasons rather than safety concerns. The approval lapsed with the product.
That detail matters. A compound that was once reviewed and approved sits on different footing than one that never was, which is part of why sermorelin is generally considered a more established, lower-drama option among growth-hormone peptides.
So how is it available now?
Today, sermorelin is available through compounding pharmacies rather than as a branded, FDA-approved product. Compounding is a legal, regulated pathway, and reputable 503B outsourcing facilities are FDA-registered and subject to inspection, sterility testing, and potency verification. But it's important to be precise: compounded sermorelin is not the same thing as an FDA-approved finished drug, and most therapeutic use in adults is off-label.
How researchers describe its mechanism
Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, the way recombinant HGH does, it's described as prompting the pituitary gland to release more of the body's own growth hormone. Researchers frame this as working through the body's existing feedback systems. That's the proposed mechanism, and it's a meaningful distinction from direct hormone replacement.
What the evidence does and doesn't say
Much of the clinical work on sermorelin dates to the era around its original approval, and the evidence for newer adult uses, like age-related GH decline or body-composition goals, is more limited than the data behind its old diagnostic role. Researchers have observed that it can raise growth-hormone levels, but the support for popular “anti-aging” framing is weaker than the marketing suggests.
We don't publish doses, schedules, or administration instructions. Even with a peptide that has sermorelin's history, those are decisions for a licensed provider who can evaluate an individual, confirm appropriate sourcing (ideally a registered 503B facility), and prescribe properly. Our role is helping you reach that provider, not replacing them.
The bottom line
Sermorelin is one of the more established peptides in the growth-hormone conversation, with a genuine regulatory history and a legitimate compounding pathway. It is still not an FDA-approved product today, and its trendier adult uses rest on thinner evidence than its backers imply. If you're considering it, a licensed provider is the right place to start, and the right place to ask exactly where the compound is coming from.